Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07107373 · ClinicalTrials.gov registry record
A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
A clinical trial of Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Bristol-Myers Squibb.
- Active
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT07107373 is a study of Obstructive Hypertrophic Cardiomyopathy (oHCM) that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 150 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07107373, a study of Obstructive Hypertrophic Cardiomyopathy (oHCM), is active but no longer recruiting, sponsored by Bristol-Myers Squibb.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US
Conditions Studied
Interventions
- DRUG Mavacamten
Study Locations (1)
California
- University of California, San Francisco (UCSF) - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2023-12-22 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07107373
The ClinicalTrials.gov registry entry for NCT07107373 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obstructive Hypertrophic Cardiomyopathy (oHCM) appearing as the primary indexed condition, and to 1 intervention - of which Mavacamten is the first listed.
NCT07107373 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07107373 about?
NCT07107373 is a clinical study titled "A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US". The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US
What is the current status of trial NCT07107373?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2023-12-22. Estimated completion is 2025-12-31.
What conditions does trial NCT07107373 study?
This clinical trial studies the following conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM).
What interventions are being tested in trial NCT07107373?
The interventions under investigation include: Mavacamten (DRUG).
Who is sponsoring clinical trial NCT07107373?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07107373 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Hypertrophic Cardiomyopathy (oHCM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.